innovent glp-1 Innovent Announces Mazdutide, First Dual

This is why supporting your body with targeted therapies can make such a visible difference

Individual tolerability varies

When Ben, a blood donor from Vermont, rolled up his sleeve to donate blood last August, he never expected to receive a message from Dr

Efficacy and safety of stem cell therapy for acute and subacute ischemic stroke: a systematic review and meta-analysis

Xu G, Song M

Phase 3 data on retatrutide (triple GLP-1/GIP/glucagon agonist) showing nearly 29% weight loss, the pending approval of CagriSema (GLP-1/amylin combination), and the arrival of oral non-peptide GLP-1 agonists like orforglipron all suggest we are at the start of a metabolic therapeutics renaissance